- Home
- ECAT vs GLPG Comparison
ECAT vs GLPG Comparison
Compare ECAT & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECAT
- GLPG
- Stock Information
- Founded
- ECAT 2021
- GLPG 1999
- Country
- ECAT United States
- GLPG Belgium
- Employees
- ECAT N/A
- GLPG N/A
- Industry
- ECAT Trusts Except Educational Religious and Charitable
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- ECAT Finance
- GLPG Health Care
- Exchange
- ECAT Nasdaq
- GLPG Nasdaq
- Market Cap
- ECAT 1.7B
- GLPG 1.8B
- IPO Year
- ECAT N/A
- GLPG 2005
- Fundamental
- Price
- ECAT $15.74
- GLPG $25.32
- Analyst Decision
- ECAT
- GLPG Sell
- Analyst Count
- ECAT 0
- GLPG 4
- Target Price
- ECAT N/A
- GLPG $25.33
- AVG Volume (30 Days)
- ECAT 278.6K
- GLPG 466.6K
- Earning Date
- ECAT 01-01-0001
- GLPG 04-23-2025
- Dividend Yield
- ECAT 9.20%
- GLPG N/A
- EPS Growth
- ECAT N/A
- GLPG N/A
- EPS
- ECAT 2.39
- GLPG N/A
- Revenue
- ECAT N/A
- GLPG $311,493,731.00
- Revenue This Year
- ECAT N/A
- GLPG N/A
- Revenue Next Year
- ECAT N/A
- GLPG N/A
- P/E Ratio
- ECAT $7.15
- GLPG N/A
- Revenue Growth
- ECAT N/A
- GLPG 18.32
- 52 Week Low
- ECAT $14.02
- GLPG $22.36
- 52 Week High
- ECAT $17.30
- GLPG $31.23
- Technical
- Relative Strength Index (RSI)
- ECAT 57.67
- GLPG 45.40
- Support Level
- ECAT $15.48
- GLPG $25.20
- Resistance Level
- ECAT $15.84
- GLPG $27.64
- Average True Range (ATR)
- ECAT 0.23
- GLPG 0.59
- MACD
- ECAT 0.12
- GLPG -0.09
- Stochastic Oscillator
- ECAT 91.89
- GLPG 23.93
About ECAT BlackRock ESG Capital Allocation Term Trust of Beneficial Interest
BlackRock ESG Capital Allocation Trust is a non-diversified, closed-ended management investment company. The Trust's investment objectives are to provide total return and income through a combination of current income, current gains, and long-term capital appreciation.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients' lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.